According to a report from Reuters on April 28th, Japan Tobacco Inc. (JT) announced on Thursday that it has suspended its investment and marketing activities in Russia last month after the invasion of Ukraine by Moscow. Currently, the company is considering selling its business in Russia.
Japan Tobacco Inc (JT) is the leading player in the Russian market and announced in March that it will continue production in Russia, where it operates four factories with 4,000 employees.
After many global brands pulled out of Ukraine due to its invasion, and various governments, including Japan, imposed severe sanctions on Moscow, this announcement has received criticism. Russia has referred to its actions in Ukraine as "special operations.
A spokesperson for JT has stated that the company is currently considering various options for its business in Russia but cannot provide any comments regarding potential buyers of its shares. In the previous fiscal year, Russia accounted for approximately 8% of JT Group's revenue and 15% of its adjusted operating profit.
The Japanese Ministry of Finance is the largest shareholder of JT, holding one-third of its shares and providing approximately $1 billion in dividend income to the government every year.
Source: Reuters
Japan Tobacco is reportedly contemplating the possibility of selling its operations in Russia. The move would divest the company of one of its key markets as it seeks to reposition its global business following declining consumption rates. The decision is expected to be made next year.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
